GSK R&D chairman
Executive Summary
Senior VP-Worldwide Business Development & External Alliances in R&D Moncef Slaoui will succeed Tadataka Yamada as GlaxoSmithKline's R&D chairman. Yamada will resign from the post effective June 1 to serve as executive director of the Bill & Melinda Gates Foundation's Global Health Program. Yamada is credited with being the "principal architect" behind the transformation and improvement of the company's R&D engine. CEO J.P. Garnier recently touted GSK's pipeline as the largest in the pharmaceutical industry based on benchmark studies (1"The Pink Sheet" Sept. 26, 2005, p. 21)...
You may also be interested in...
GSK Senior VP-Worldwide Business Development
GlaxoSmithKline's incoming Senior VP-Worldwide Business Development, Research & Development Adrian Rawcliffe has a background in deal-making for GSK; Rawcliffe was most recently managing partner and president of GSK's venture capital business, SR One Ltd. He previously served as GSK's VP-Genetics & Discovery Deal Structuring and VP-Transactions & Ventures. Rawcliffe succeeds Moncef Slaoui, who moved up to the position of chairman of R&D earlier this year (1"The Pink Sheet" Feb. 13, 2006, In Brief)...
GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?
GlaxoSmithKline plans to end 2006 with six product launches and six regulatory filings, CEO J.P. Garnier said during a presentation at the Bear Stearns Healthcare conference in New York Sept. 13
Colfax Plans To Split To Form Separate Medtech And Fabtech Companies
The yet-to-be-named medtech company will focus on orthopedic implants and bracing and recovery devices.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: